Patent US6764509B2 successfully refreshed from Google Patents.
US6764509B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prosthetic heart valve with surface modification
Assignee: Corcym SRL
•
Filing: 2000-12-21
•
Granted: 2004-07-20
•
Expires: 2020-12-21
Abstract
Abstract Biocompatible prostheses, specifically, biocompatible heart valves, are described having incorporated therein an effective amount of coating applied thereto to render the valve resistant to in vivo pathologic thrombus formation and in vivo pathologic mineralization. Preferably, the coating is derived from a precursor having the formula: X—Y—Z wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y is either null or a relatively inert skeletal moiety resistant to cleavage in aqueous physiological fluids; and Z is a functionally active moiety or a biocompatible agent.
Inventors
- 👤 Joseph Andrew Chinn
- 👤 Jack R. Frautschi
- 👤 Richard E. Phillips, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 22:48
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/28; A61L27/34; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2412
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
131 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula: X—Y—Z wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y comprises a compound selected from the group consisting of a C 1 -C 10 alkyldiol; a C 1 -C 10 diamine; a polyethyleneoxide (PEO); an amino-substituted PEO (MW=200-1450); a diamine-terminated PEO (MW=200-1450); ε-amino caproic acid (EAC); ethylene diamine (ED); diaminopropane (DAP), and derivatives of the foregoing; and Z is a fatty acid moiety, a hyaluronic acid moiety, a polyoxyethylene moiety, or a vinylpyrrolidone moiety.
Claim 2
Dependent Claim
131 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula: X—Y—Z wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y comprises a compound selected from the group consisting of a C 1 -C 10 alkyldiol; a C 1 -C 10 diamine; a polyethyleneoxide (PEO); an amino-substituted PEO (MW=200-1450); a diamine-terminated PEO (MW=200-1450); ε-amino caproic acid (EAC); ethylene diamine (ED); diaminopropane (DAP), and derivatives of the foregoing; and Z is a fatty acid moiety, a hyaluronic acid moiety, a polyoxyethylene moiety, or a vinylpyrrolidone moiety.
Claim 3
Dependent Claim
108 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula: X—Y—Z wherein X is selected from the group consisting of a substituted benzyl benzoyl having structure I: wherein R1 is a carboxyl group, and derivatives thereof; Y comprises diaminopropane (DAP), a diamine-terminated amide, and derivatives of diaminopropane and diamine-terminated amides; and, Z is derived from a compound selected from functionalized fatty acids, functionalized hyaluronic acid, functionalized polyoxyethylene, functionalized heparin, or functionalized vinylpyrrolidone.
Claim 4
Dependent Claim
108 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula: X—Y—Z wherein X is selected from the group consisting of a substituted benzyl benzoyl having structure I: wherein R1 is a carboxyl group, and derivatives thereof; Y comprises diaminopropane (DAP), a diamine-terminated amide, and derivatives of diaminopropane and diamine-terminated amides; and, Z is derived from a compound selected from functionalized fatty acids, functionalized hyaluronic acid, functionalized polyoxyethylene, functionalized heparin, or functionalized vinylpyrrolidone.
Claim 5
Dependent Claim
55 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor selected from the group consisting of: and derivatives of (II) and (III).
Claim 6
Dependent Claim
55 words
A biocompatible heart valve comprising: a stent defining a blood flow path; and a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor selected from the group consisting of: and derivatives of (II) and (III).
References Cited (Backward Citations)
US3954583A
Cited
US4116898A
Cited
US4363142A
Cited
US4364127A
Cited
US5002582A
Cited
US4613517A
Cited
US4751120A
Cited
US5263992A
Cited
US4979959A
Cited
US5017670A
Cited
US5098977A
Cited
US5098960A
Cited
US5112615A
Cited
US5126140A
Cited
US5167960A
Cited
US5019393A
Cited
US5509932A
Cited
US5554184A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2007-07-20 | 2008-01-19 | 2008-07-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2011-07-20 | 2012-01-19 | 2012-07-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2015-07-20 | 2016-01-19 | 2016-07-20 | $7700.00 | Window Closed / Lapsed |